{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:00:24Z","timestamp":1787238024271,"version":"build-2736575974"},"reference-count":62,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Densitometry"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1016\/j.jocd.2005.09.004","type":"journal-article","created":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T17:11:45Z","timestamp":1149181905000},"page":"58-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Ibandronate: The Evolution of a Once-a-Month Oral Therapy for Postmenopausal Osteoporosis"],"prefix":"10.1016","volume":"9","author":[{"given":"David W.","family":"Dempster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Bolognese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocd.2005.09.004_bib1","unstructured":"Siris ES, Rosen CJ, Harris ST, Abbott TA III, Barr CE, Silverman SL. 2005 Adherence rates to bisphosphonate therapy: relationship to bone fractures at 24 months in women with postmenopausal osteoporosis. Proc 6th International Symposium on Osteoporosis: Current Status and Future Directions, the National Osteoporosis Foundation, Washington, DC, 2005."},{"key":"10.1016\/j.jocd.2005.09.004_bib2","unstructured":"US Department of Health and Human Services. 2004 Bone health and osteoporosis: a report of the Surgeon General (2004). Available at: http:\/\/www.hhs.gov\/surgeongeneral\/library\/bonehealth\/content.html. Accessed April 6, 2005."},{"key":"10.1016\/j.jocd.2005.09.004_bib3","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1179\/acb.2002.054","article-title":"Management of primary osteoporosis","volume":"57","author":"Body","year":"2002","journal-title":"Acta Clin Belg"},{"key":"10.1016\/j.jocd.2005.09.004_bib4","unstructured":"National Osteoporosis Foundation. 2004 Osteoporosis fast facts. Available at: http:\/\/www.nof.org\/osteoporosis\/diseasefacts.htm. Accessed February 7, 2005."},{"key":"10.1016\/j.jocd.2005.09.004_bib5","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/jbmr.5650100202","article-title":"How many women have osteoporosis now?","volume":"10","author":"Melton","year":"1995","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2005.09.004_bib6","unstructured":"Cooper C. 1996 Epidemiology and Definition of Osteoporosis. In: Osteoporosis: New Perspectives on Causes, Prevention, and Treatment. Compston JE, ed. Royal College of Physicians, London, 1\u201310."},{"key":"10.1016\/j.jocd.2005.09.004_bib7","doi-asserted-by":"crossref","unstructured":"Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Introduction. 1998 Osteoporos Int 8(Suppl 4):S7\u2013S80.","DOI":"10.1007\/PL00022721"},{"key":"10.1016\/j.jocd.2005.09.004_bib8","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/00006254-200406000-00023","article-title":"Hip fracture prevention in postmenopausal women","volume":"59","author":"Kessel","year":"2004","journal-title":"Obstet Gynecol Surv"},{"key":"10.1016\/j.jocd.2005.09.004_bib9","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1001\/archinte.159.11.1215","article-title":"Vertebral fractures and mortality in older women: a prospective study","volume":"159","author":"Kado","year":"1999","journal-title":"Arch Intern Med"},{"issue":"Suppl 2A","key":"10.1016\/j.jocd.2005.09.004_bib10","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/S0002-9343(05)80037-3","article-title":"The economic and human costs of osteoporotic fracture","volume":"98","author":"Barrett-Connor","year":"1995","journal-title":"Am J Med"},{"key":"10.1016\/j.jocd.2005.09.004_bib11","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebal fractures","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.jocd.2005.09.004_bib12","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/PL00004171","article-title":"Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax\u00ae International Trial Study Group","volume":"9","author":"Pols","year":"1999","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2005.09.004_bib13","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2005.09.004_bib14","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jocd.2005.09.004_bib15","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jocd.2005.09.004_bib16","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/jama.280.7.605","article-title":"Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women","volume":"280","author":"Hulley","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.jocd.2005.09.004_bib17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/jama.288.1.49","article-title":"Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen\/progestin Replacement Study follow-up (HERS II)","volume":"288","author":"Grady","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jocd.2005.09.004_bib18","doi-asserted-by":"crossref","first-page":"856","DOI":"10.4065\/80.7.856","article-title":"Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women","volume":"80","author":"Recker","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jocd.2005.09.004_bib19","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.maturitas.2004.02.005","article-title":"Compliance with drug therapies for the treatment and prevention of osteoporosis","volume":"48","author":"McCombs","year":"2004","journal-title":"Maturitas"},{"key":"10.1016\/j.jocd.2005.09.004_bib20","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00198-004-1652-z","article-title":"The impact of compliance with osteoporosis therapy on fracture rates in actual practice","volume":"15","author":"Caro","year":"2004","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2005.09.004_bib21","unstructured":"Harris ST, Siris E, Abbott TA, Barr CE, Rosen CJ. 2005 Reduced osteoporotic fracture risk in patients adherent to bisphosphonate therapy. Proc ENDO 2005 Annual Meeting, San Diego, CA, 2005."},{"key":"10.1016\/j.jocd.2005.09.004_bib22","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1046\/j.1365-2133.2000.03479.x","article-title":"Once weekly fluconazole is effective in children in the treatment of tinea capitis: a prospective, multicentre study","volume":"142","author":"Gupta","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jocd.2005.09.004_bib23","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4088\/JCP.v63n0310","article-title":"Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression","volume":"63","author":"Miner","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jocd.2005.09.004_bib24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00004850-200505000-00001","article-title":"Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies","volume":"20","author":"Moller","year":"2005","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.jocd.2005.09.004_bib25","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.contraception.2003.10.006","article-title":"The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra) on contraceptive efficacy","volume":"69","author":"Archer","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.jocd.2005.09.004_bib26","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1359\/JBMR.050313","article-title":"Monthly oral ibandronate in postmenopausal osteoporosis: 1-year results from the MOBILE study","volume":"20","author":"Miller","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2005.09.004_bib27","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1517\/13543784.12.4.611","article-title":"Novel therapies for osteoporosis","volume":"12","author":"Biskobing","year":"2003","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jocd.2005.09.004_bib28","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1742-1241.2003.tb10518.x","article-title":"Ibandronate: a potent new bisphosphonate in the management of postmenopausal osteoporosis","volume":"57","author":"Papapoulos","year":"2003","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jocd.2005.09.004_bib29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0093-7754(01)90232-5","article-title":"Dosing regimens and main adverse events of bisphosphonates","volume":"28","author":"Body","year":"2001","journal-title":"Semin Oncol"},{"issue":"5 Suppl","key":"10.1016\/j.jocd.2005.09.004_bib30","first-page":"S209","article-title":"Short-term compliance with alendronate 70 mg in patients with osteoporosis: the ECMO trial","volume":"25","author":"Negri","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.jocd.2005.09.004_bib31","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/S0149-2918(02)80085-6","article-title":"Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study","volume":"24","author":"Simon","year":"2002","journal-title":"Clin Ther"},{"key":"10.1016\/j.jocd.2005.09.004_bib32","first-page":"945","article-title":"Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 6. Use of bisphosphonates in the treatment of osteoporosis","volume":"155","author":"Hodsman","year":"1996","journal-title":"CMAJ"},{"key":"10.1016\/j.jocd.2005.09.004_bib33","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S8756-3282(99)00116-7","article-title":"Bisphosphonates: from the laboratory to the clinic and back again","volume":"25","author":"Russell","year":"1999","journal-title":"Bone"},{"key":"10.1016\/j.jocd.2005.09.004_bib34","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/BF02738966","article-title":"Bisphosphonates in the treatment of osteoporosis","volume":"6","author":"Bell","year":"1997","journal-title":"Endocrine"},{"key":"10.1016\/j.jocd.2005.09.004_bib35","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.2174\/1381612033453640","article-title":"New insights into the molecular mechanisms of action of bisphosphonates","volume":"9","author":"Rogers","year":"2003","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jocd.2005.09.004_bib36","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1359\/jbmr.2003.18.2.204","article-title":"Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro","volume":"18","author":"Frith","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2005.09.004_bib37","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0022-3565(24)38786-5","article-title":"Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates","volume":"296","author":"Dunford","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jocd.2005.09.004_bib38","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/jbmr.5650060915","article-title":"BM 21.0955, a potent new bisphosphonate to inhibit bone resorption","volume":"6","author":"M\u00fchlbauer","year":"1991","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2005.09.004_bib39","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00198-004-1612-7","article-title":"Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing","volume":"15","author":"Bauss","year":"2004","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2005.09.004_bib40","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0149-2918(03)90005-1","article-title":"Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies","volume":"25","author":"Schimmer","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.jocd.2005.09.004_bib41","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1185\/030079905X30752","article-title":"Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE","volume":"21","author":"Chesnut","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jocd.2005.09.004_bib42","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s00198-004-1602-9","article-title":"Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study","volume":"15","author":"Delmas","year":"2004","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2005.09.004_bib43","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2005.09.004_bib44","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/0091270004267594","article-title":"Ibandronate: a clinical pharmacological and pharmacokinetic update","volume":"44","author":"Barrett","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jocd.2005.09.004_bib45","series-title":"Boniva\u00ae(ibandronate sodium) tablets","year":"2005"},{"key":"10.1016\/j.jocd.2005.09.004_bib46","first-page":"990","article-title":"Total administered dose of ibandronate determines its effects on bone mass and architecture in ovariectomized aged rats","volume":"29","author":"Bauss","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jocd.2005.09.004_bib47","first-page":"2200","article-title":"Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats","volume":"29","author":"Bauss","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jocd.2005.09.004_bib48","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF02672503","article-title":"Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats","volume":"8","author":"Lalla","year":"1998","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2005.09.004_bib49","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0300-483X(03)00257-9","article-title":"The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats","volume":"191","author":"Pfister","year":"2003","journal-title":"Toxicology"},{"key":"10.1016\/j.jocd.2005.09.004_bib50","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1359\/jbmr.1999.14.10.1768","article-title":"Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: effects on bone morphometry and mineral properties","volume":"14","author":"Monier-Faugere","year":"1999","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2005.09.004_bib51","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S8756-3282(02)00923-7","article-title":"Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys","volume":"32","author":"Smith","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.jocd.2005.09.004_bib52","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1359\/JBMR.040809","article-title":"Intermittent ibandronate preserves bone quality and bone strength in the lumbar spine after 16 months of treatment in the ovariectomized cynomolgus monkey","volume":"19","author":"Muller","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2005.09.004_bib53","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.vascn.2003.11.003","article-title":"New model for simulation of fracture repair in full-grown beagle dogs: model characterization and results from a long-term study with ibandronate","volume":"50","author":"Bauss","year":"2004","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.jocd.2005.09.004_bib54","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S8756-3282(03)00091-7","article-title":"Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens","volume":"32","author":"Tanko","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.jocd.2005.09.004_bib55","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/BF03324509","article-title":"Injectable bisphosphonates in the treatment of postmenopausal osteoporosis","volume":"15","author":"Sartori","year":"2003","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.jocd.2005.09.004_bib56","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.bone.2004.01.007","article-title":"Efficacy and safety of ibandronate given by intravenous injection once every 3 months","volume":"34","author":"Adami","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.jocd.2005.09.004_bib57","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0002-9343(97)00249-0","article-title":"Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis","volume":"103","author":"Thiebaud","year":"1997","journal-title":"Am J Med"},{"key":"10.1016\/j.jocd.2005.09.004_bib58","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1136\/ard.62.10.969","article-title":"Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women","volume":"62","author":"Stakkestad","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jocd.2005.09.004_bib59","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.bone.2004.01.008","article-title":"Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis","volume":"34","author":"Recker","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.jocd.2005.09.004_bib60","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1359\/jbmr.2001.16.10.1871","article-title":"Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis","volume":"16","author":"Riis","year":"2001","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2005.09.004_bib61","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1210\/jc.2003-022029","article-title":"Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis","volume":"88","author":"Cooper","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2005.09.004_bib62","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1365-2796.2003.01174.x","article-title":"Oral weekly ibandronate prevents bone loss in postmenopausal women","volume":"254","author":"Tanko","year":"2003","journal-title":"J Intern Med"}],"container-title":["Journal of Clinical Densitometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094695006000187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094695006000187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:33:16Z","timestamp":1761082396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094695006000187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["S1094695006000187"],"URL":"https:\/\/doi.org\/10.1016\/j.jocd.2005.09.004","relation":{},"ISSN":["1094-6950"],"issn-type":[{"value":"1094-6950","type":"print"}],"subject":[],"published":{"date-parts":[[2006,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ibandronate: The Evolution of a Once-a-Month Oral Therapy for Postmenopausal Osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Densitometry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocd.2005.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 The International Society for Clinical Densitometry. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}